Informasjon

Acetylcystein

Acetylcystein brukes som motgift ved forgiftninger med paracetamol. Men acetylcystein har også vist seg å virke ved en rekke andre tilstander.

Oppsummert

Acetylcystein er en trygg, rimelig og godt tolerert antioksidant med en kjent virkningsmekanisme. Det er den foretrukne motgiften ved paracetamolforgiftning. Brukt i doser under 1200 mg per døgn gir midlet få bivirkninger. Noen pasienter med KOLS, kronisk bronkitt og cystisk fibrose, kan ha nytte av acetylcystein. Midlet kan også bidra til å forebygge kontrastindusert nyreskade, dempe influensaplager og øke effekten av Klomifen ved polycystisk ovariesyndrom.

Kilder

Referanser

  1. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev, issue 2, 2006. CD003328. Cochrane (DOI)
  2. Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician 2009; 80: 265-9. American Family Physician
  3. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
  4. Dickinson DA, Moellering DR, Iles KE, et al. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. Biol Chem 2003; 384: 527–37.
  5. Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis—a study in general practice. J Int Med Res. 1983; 11: 279–284.
  6. Lundbäck B, Lindström M, Andersson S, Nyström �L, Rosenhall L, Stjernberg N. Possible effect of acetylcysteine on lung function. Eur Respir J 1992; 5(suppl 15): 289.
  7. Stey C, Steurer J, Bachmann S, Medici TC, Tramür MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253–62.
  8. Decramer M, Ruttenvan Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–60.
  9. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–64.
  10. Van Praet JT, De Vriese AS. �Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 2007; 16: 336–47.
  11. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009; 122: 874.e9-15.
  12. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535–41.
  13. Demedts M, Behr J, Buhl R, et al., for the IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229–42.
Forrige side